Illumina, Inc. (ticker: ILMN, exchange: NASDAQ Global Select Market (.O))
News Release -
Illumina Names David Douglas as Vice President of Manufacturing
SAN DIEGO, CALIFORNIA, January 5, 2001 -- Illumina, Inc. (Nasdaq: ILMN) announced today the appointment of David C. Douglas as Vice President of Manufacturing. Mr. Douglas will be responsible for the fabrication and quality control of all bead-based microarray products, related hardware, and software offerings being developed around Illumina's high-throughput BeadArrayŌ technology platform. In his new position, Douglas will also oversee the synthesis of oligonucleotides (oligos), short DNA sequences fundamental to microarray assembly and to many of the experimental assays used increasingly in functional genomics research.
Mr. Douglas brings to Illumina over 20 years of experience in materials and operations management for high-technology firms. He served most recently as Vice President of Operations at POSDATA, where he led efforts to build an integrated network of service and technical support facilities. In earlier roles at Acuson Computed Sonography and Plexus Computers, he held various production, materials and manufacturing engineering positions. Mr. Douglas holds a B.S. in Electrical Engineering from the Oregon Institute of Technology.
Jay Flatley, Illumina President and CEO, commented, "Dave Douglas brings proven, product manufacturing experience to Illumina and rounds out a seasoned management team. We welcome Dave to Illumina and look forward to his contributions in supporting the commercialization of our BeadArray platform."
Illumina (www.illumina.com) is developing next-
generation tools that will permit the large-scale analysis of genetic variation and function. The information provided by these analyses will enable the development of personalized medicine, a key goal of genomics and proteomics. The Company's proprietary BeadArrayŌ technology will provide the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics. This information will correlate genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients. Illumina's technology will have applicability across a wide variety of industries beyond life sciences and pharmaceuticals, including agriculture, food, chemicals and petrochemicals.
Statements included in this press release that are not historical in nature may be "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Any such forward-looking statements involve risks and uncertainties and reflect Illumina's judgement as of the date of this release. Actual events or results may differ from Illumina's expectations as a result of risks and uncertainties, identified from time to time in Illumina's reports filed with the U.S. Securities and Exchange Commission, including those discussed in "Risk Factors" and elsewhere in the Company's Registration Statement on Form S-1, as amended (File No. 333-33922), available via Illumina's website at http://www.illumina.com. In addition, Illumina may not be successful in commercializing its BeadArray system. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release and claims the protection of the Safe Harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.